Management of Hyperglycemia in Type 2 Diabetes

A Consensus Algorithm for the Initiation and Adjustment of TherapyA consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

  • NATHAN, DAVID M. MD
  • BUSE, JOHN B. MD, PHD
  • DAVIDSON, MAYER B. MD
  • HEINE, ROBERT J. MD
  • HOLMAN, RURY R. FRCP
  • SHERWIN, ROBERT MD
  • ZINMAN, BERNARD MD

  • 1Diabetes Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts

    2University of North Carolina School of Medicine, Chapel Hill, North Carolina

    3Clinical Trials Unit, Charles R. Drew University, Los Angeles, California

    4Diabetes Center, VU University Medical Center, Amsterdam, the Netherlands

    5Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, Oxford University, Oxford, U.K.

    6Department of Internal Medicine and Endocrinology, Yale University School of Medicine, New Haven, Connecticut

    7Departments of Endocrinology and Metabolism, Mount Sinai Hospital, University of Toronto, Toronto, Canada

Address correspondence and reprint requests to David M. Nathan, MD, Diabetes Center, Massachusetts General Hospital, Boston, MA 02114. E-mail: [email protected]

This document was reviewed and approved by the Professional Practice Committee of the American Diabetes Association and by an ad hoc committee of the European Association for the Study of Diabetes (Ulf Smith, Gothenburg, Sweden; Stefano Del Prato, Pisa, Italy; Clifford Bailey, Birmingham U.K.; and Bernard Charbonnel, Nantes, France).

D.M.N. has received research grants for investigator-initiated research from Aventis and Novo Nordisk. J.B.B. has conducted research and/or served on advisory boards under contract between the University of North Carolina and Amylin, Becton Dickinson, Bristol-Myers Squibb, Hoffman-LaRoche, Lilly, Novo Nordisk, Merck, Novartis, Pfizer, and Sanofi-Aventis. M.B.D. has received research support from Eli Lilly, Merck, and Pfizer; has served on advisory boards for Amylin, GlaxoSmithKline, Merck, Sanofi-Aventis; and has been on speakers bureaus for Amylin, Eli Lilly, GlaxoSmithKline, and Pfizer. R.J.H. has received research support from GlaxoSmithKline, Minimed-Medtronic, Novartis, and Novo Nordisk and has served on advisory boards for Amylin, Bristol-Myers Squibb, Merck, Novartis, Novo Nordisk, Pfizer, and Sanofi-Aventis. R.R.H. has received research support from Bristol-Myers Squibb, GlaxoSmithKline, Merck Santé, Novo Nordisk, Pfizer, and Pronova and has served on advisory boards and/or received honoraria for speaking engagements from Amylin, GlaxoSmithKline, Lilly, Merck Sharp & Dome, Novartis, and Sanofi-Aventis. R.S. has served on advisory boards for Amylin, Bristol-Myers Squibb, Eli Lilly, Merck, and Takeda. B.Z. has received research support from Eli Lilly, GlaxoSmithKline, Novartis, and Novo Nordisk and has been a member of scientific advisory boards and/or received honoraria for speaking engagements from Amylin, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Sanofi-Aventis, and Smiths Medical.

Simultaneous publication: This article is being simultaneously published in 2006 in Diabetes Care and Diabetologia by the American Diabetes Association and the European Association for the Study of Diabetes.

Posted on the World Wide Web at http://care.diabetesjournals.org on 27 June 2006.

© 2006 by the American Diabetes Association, Inc., and Springer-Verlag. Copying with attribution allowed for any noncommercial use of the work.

Abbreviations: CVD, cardiovascular disease; DCCT, Diabetes Control and Complications Trial; GLP-1, glucagon-like peptide 1; SMBG, self-monitoring of blood glucose; TZD, thiazolidinedione; UKPDS, U.K. Prospective Diabetes Study
Diabetes Care 29(8):p 1963-1972, August 2006.
Copyright © 2006 by the American Diabetes Association, Inc.